These findings suggest that these ratios have potential diagnostic and prognostic applications that can be applied in clinical settings to differentiate between sickle Hb subgroups, assess disease complications, and guide personalized management strategies for sickle cell disease (SCD) patients. The gene discussed is GSTM1; the disease is sickle cell disease.